Stocktoria
Viking Therapeutics, Inc. VKTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-04-29
Viking Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $345.0M | $101.6M | $63.8M | $54.2M | $45.0M |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M |
| Income tax | $1,000 | $1,000 | $1,000 | $1,000 | $2,000 |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M |
| EPS (diluted) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 |
| Operating cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M |
| Cash & equivalents | $165.8M | $26.7M | $55.5M | $36.6M | $26.4M |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M |
| Shareholders' equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M |
Source: SEC EDGAR filings · CIK 0001607678 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.